Prescient Therapeutics Limited (PTX) AI Stock Analysis

• Market Cap: AU$79.92M
• Dividend Yield: N/A
• Average Volume (3M): 690.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: N/A
• EPS Growth: 10.78%
• Country: AU
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 1,051,514,500
• 10 Day Avg. Volume: 838,009
• 30 Day Avg. Volume: 690,151
• PEG Ratio: 0.45
• Price to Book (P/B): 3.11
• Price to Sales (P/S): 8.13
• P/FCF Ratio: -4.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: AU$0.07 ▼(-12.50% Downside)

The score is held back primarily by ongoing losses and persistent negative free cash flow despite strong revenue growth, which increases reliance on external funding. Technicals are moderately supportive with price above key long-term averages, but valuation remains constrained by unprofitability and no dividend support.

Positive Factors

Revenue Growth

Strong revenue growth indicates increasing market acceptance and potential scalability of Prescient's oncology therapies, supporting long-term expansion.

Regulatory Milestone

EU trial approval for PTX-100 marks a significant step in clinical development, enhancing Prescient's potential to address unmet medical needs in CTCL.

Orphan Drug Designation

Orphan Drug Designation provides market exclusivity, supporting Prescient's strategic positioning and potential revenue streams in the EU oncology market.

Negative Factors

Operating Losses

Ongoing operating losses highlight financial challenges, requiring sustained external funding and impacting long-term profitability potential.

Negative Cash Flow

Negative free cash flow indicates high cash burn, necessitating external capital to maintain operations, which could limit financial flexibility.

Equity Dilution

Declining equity suggests potential dilution risks, affecting shareholder value and reflecting ongoing financial strain from operational losses.

Prescient Therapeutics Limited Business Overview & Revenue Model

Company Description

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

How the Company Makes Money

Prescient Therapeutics Limited makes money primarily through the development and licensing of its proprietary cancer therapies. The company generates revenue through partnerships and collaborations with other pharmaceutical and biotechnology companies, which may include milestone payments, licensing fees, and royalties on successful commercialization of its therapies. Additionally, PTX may receive funding from grants and government initiatives to support its research and development activities. The company's focus on innovative treatment solutions attracts investment interest, aiding its financial sustainability and growth.

Prescient Therapeutics Limited Financial Statement Overview

Summary

Revenue growth is strong (2025 up ~44% YoY) and leverage is low, but results remain dominated by persistent operating losses and negative free cash flow, with cash burn worsening most recently (2025 FCF down ~25% YoY).

Income Statement

Revenue has grown meaningfully over the period (2025 revenue up ~44% year over year), and reported gross profit is consistently high. However, the company remains structurally loss-making with persistently negative operating profit and net income each year, and profitability has not yet reached an inflection point despite improving revenue. Overall, the income statement reflects early-stage scale-up progress but continued heavy operating spend relative to the current revenue base.

Balance Sheet

The balance sheet is relatively conservative with minimal to no debt in most years (very low leverage where debt exists), which reduces refinancing and interest-rate risk. That said, equity and total assets have declined from earlier peaks, and returns on equity are consistently negative, indicating ongoing value dilution/consumption from losses. Overall financial flexibility appears adequate, but continued losses pressure the capital base over time.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are negative every year, consistent with a cash-consuming biotech model. Free cash flow also deteriorated in the most recent year (2025 down ~25% year over year), highlighting a higher cash burn profile despite revenue growth. While cash outflows broadly track the net loss (free cash flow roughly in line with net income), the company remains dependent on external funding to sustain operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.36M	4.36M	3.71M	2.43M	1.89M	1.19M
Gross Profit	4.36M	4.36M	3.71M	2.43M	1.89M	1.19M
EBITDA	-7.53M	-7.54M	-7.19M	-7.46M	-6.86M	-5.32M
Net Income	-7.32M	-7.32M	-8.24M	-7.00M	-5.12M	-4.15M
Balance Sheet
Total Assets	14.56M	14.56M	20.39M	28.11M	17.62M	20.97M
Cash, Cash Equivalents and Short-Term Investments	6.93M	6.93M	14.51M	21.92M	12.28M	16.12M
Total Debt	0.00	0.00	330.49K	0.00	0.00	165.83K
Total Liabilities	3.17M	3.17M	2.33M	2.03M	856.01K	539.68K
Stockholders Equity	11.39M	11.39M	18.07M	26.08M	16.76M	20.43M
Cash Flow
Free Cash Flow	-7.24M	-7.24M	-7.40M	-6.19M	-4.32M	-3.97M
Operating Cash Flow	-7.24M	-7.24M	-7.40M	-6.19M	-4.31M	-3.97M
Investing Cash Flow	4.00M	4.00M	12.00M	-16.00M	-4.43K	-2.31K
Financing Cash Flow	-660.97K	-330.49K	18.15K	15.83M	428.29K	12.75M

Prescient Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PTX, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.84 is Neutral, neither overbought nor oversold. The STOCH value of 25.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PTX.

Prescient Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PTX	50 Neutral	AU$79.92M	-8.35	-49.72%	―	―	10.78%
SPL	48 Neutral	AU$142.77M	-16.46	-41.51%	―	-40.74%	-21.21%
CYP	46 Neutral	AU$81.92M	-7.08	-138.54%	―	―	16.61%
CHM	45 Neutral	AU$11.05M	―	-469.35%	―	―	46.28%
AVE	44 Neutral	AU$33.06M	-9.09	-143.71%	―	306.88%	―
ALA	44 Neutral	AU$105.70M	-13.24	-47.98%	―	700.00%	26.88%

Prescient Therapeutics Limited Corporate Events

Prescient Wins EU Orphan Status for PTX‑100, Advances Global CTCL Trial and Cell Therapy Platforms

Prescient Therapeutics reported steady progress in the December 2025 quarter, highlighted by the European Medicines Agency granting Orphan Drug Designation for PTX‑100 in cutaneous T‑cell lymphoma and European authorisation to commence a Phase 2a trial in relapsed/refractory CTCL. The company expanded its global clinical footprint with additional trial sites in Australia, the US and Italy, advanced patient screening and enrolment toward a target of up to 40 patients, and continued exploring further development in peripheral T‑cell lymphoma. It ended the quarter with $9.7 million in cash and subsequently received a $4.3 million R&D tax rebate, keeping operating expenditure in line with budget, while progressing partnering discussions for its CellPryme‑M platform and preparing to resume development of its OmniCAR platform with an appropriate partner, underscoring a broader strategy to strengthen its position in targeted oncology and cell therapy.

The most recent analyst rating on (AU:PTX) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Prescient Therapeutics Limited stock, see the AU:PTX Stock Forecast page.

Prescient Therapeutics Issues 21.78m Unquoted Options Under Employee Incentive Plan

Prescient Therapeutics Limited has issued 21.78 million unquoted options under its employee incentive scheme, exercisable at A$0.10 and expiring on 17 November 2029. The move is designed to align staff incentives with long-term shareholder value and supports the company’s efforts to retain and motivate key employees as it advances its oncology drug development pipeline.

Prescient Therapeutics Gains EU Approval for PTX-100 CTCL Trial

Prescient Therapeutics Limited has received authorization from the European Clinical Trials Information System to commence a Phase 2a clinical trial of PTX-100 in Italy for patients with relapsed/refractory Cutaneous T-cell Lymphoma (CTCL). This milestone allows the company to activate trial sites and begin patient recruitment, marking a significant step towards providing a new treatment option for CTCL, a disease with high unmet medical needs.

Prescient Therapeutics Announces Director’s Interest Change

Prescient Therapeutics Limited announced a change in the director’s interest, specifically regarding Dr. Gavin Shepherd. The change involves the acquisition of 1,213,787 unlisted options exercisable at $0.10, expiring on 17 November 2029. This issuance of options was approved by shareholders at the company’s Annual General Meeting. Such changes in director interests can influence stakeholder perceptions and reflect strategic decisions aligned with the company’s growth and operational objectives.

Prescient Therapeutics Announces Director’s Change in Securities Interest

Prescient Therapeutics Limited announced a change in the director’s interest, with Ellen Gwen Feigal acquiring 1,213,787 unlisted options exercisable at $0.10, expiring on 17 November 2029. This issuance of options was approved by shareholders at the company’s Annual General Meeting, reflecting a strategic move to align the interests of the director with the company’s long-term goals, potentially impacting its governance and stakeholder confidence.

Director’s Interest Update at Prescient Therapeutics

Prescient Therapeutics Limited announced a change in the director’s interest, with Melanie Farris acquiring 2,628,787 unlisted options exercisable at $0.10 each, expiring on November 17, 2029. This acquisition was approved by shareholders at the company’s Annual General Meeting, indicating a strategic move to align the director’s interests with the company’s long-term growth and shareholder value.

Prescient Therapeutics Announces Director’s Acquisition of Options

Prescient Therapeutics Limited announced a change in the director’s interest, with Allen James Ebens Jr. acquiring 2,628,787 unlisted options exercisable at $0.10, expiring on 17 November 2029. This issuance of options was approved by shareholders at the company’s Annual General Meeting, indicating a strategic move to align the interests of the director with the company’s long-term goals.

Prescient Therapeutics Director Acquires New Options

Prescient Therapeutics Limited announced a change in the director’s interest, with James Campbell acquiring 5,257,573 unlisted options exercisable at $0.10, expiring on 17 November 2029. This change was approved by shareholders at the company’s Annual General Meeting, indicating strategic alignment and potential growth opportunities for the company.

Prescient Therapeutics Gains EU Orphan Drug Designation for PTX-100

Prescient Therapeutics Limited has secured Orphan Drug Designation from the European Medicines Agency for PTX-100, a therapy for cutaneous T-cell lymphoma (CTCL), which provides significant benefits such as 10 years of market exclusivity in the EU upon approval. This designation underscores the urgent need for new CTCL treatments and validates PTX-100’s potential to benefit patients across Europe, enhancing Prescient’s commercial pathway in key markets.

Prescient Therapeutics Issues New Employee Incentive Options

Prescient Therapeutics Limited announced the issuance of 12,942,721 unquoted equity securities in the form of options expiring on November 17, 2029, with an exercise price of $0.10. This move is part of an employee incentive scheme and is not intended for quotation on the ASX, reflecting the company’s strategy to incentivize and retain talent, potentially impacting its operational capabilities and market position.